Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

KNS-760704

150 mg Q12H KNS-760704 given orally (300 mg total daily dose)

Trial Locations (19)

10032

Columbia University, Lou Gehrig MDA/ALS Research Center, New York

13210

SUNY Upstate Medical University, Syracuse

15213

University of Pittsburgh School of Medicine, Pittsburgh

17033

Penn State Hershey Medical Center, Hershey

19102

Drexel University College Of Medicine, Philadelphia

21228

Johns Hopkins University School of Medicine, Baltimore

22908

University of Virginia Health System, Charlottesville

33136

University of Miami Miller School of Medicine, Miami

37232

Vanderbilt University Medical Center, Nashville

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

68506

Bryan LGH Medical Center East, Lincoln

72205

University of Arkansas for Medical Sciences, Little Rock

78229

University of Texas Health Sciences Center of San Antonio, San Antonio

84132

University of Utah, Salt Lake City

90095

UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles

94115

The Forbes Norris MDA/ALS Research Center, San Francisco

98195

University of Washington, Seattle

02129

Massachusettes General Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Knopp Biosciences

INDUSTRY